MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Park, Jeong Youp ^a,b,c   Hiroshima, Yukihiko ^a,b,d   Lee, Jin Young ^c   Maawy, Ali A ^a   Hoffman, Robert M ^a,b   Bouvet, Michael ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b ANTICANCER INC   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; MUC1 ANTIBODY; MUCIN 1; UNCLASSIFIED DRUG; FLUORESCENT DYE; MONOCLONAL ANTIBODY; MUC1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BXPC 3 CELL LINE; CANCER DIAGNOSIS; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PANC 1 CELL LINE; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR MODEL; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CHEMISTRY; FLUORESCENCE IMAGING; GENETIC PROCEDURES; HUMAN; IMMUNOCHEMISTRY; IMMUNOLOGY; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOSENSING TECHNIQUES; CELL LINE, TUMOR; FLUORESCENT DYES; HUMANS; IMMUNOCHEMISTRY; MICE; MICE, NUDE; MUCIN-1; OPTICAL IMAGING; PANCREATIC NEOPLASMS;

EID: 84929484604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122100     Document Type: Article

References (33)

1. Bunger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137:375-389. doi: 10.1007/s00432-010-0965-x PMID: 21193998
2. Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics. 2005;4:523-533. PMID: 15684406
3. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893-2904. doi: 10.1038/onc.2010.87 PMID: 20348949
4. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001;6:339-353. PMID: 11547902
5. Qu CF, Li Y, Song YJ, Rizvi SM, Raja C, Zhang D, et al. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213) Bi-C595 radioimmunoconjugate. Br J Cancer. 2004;91:2086-2093. PMID: 15599383
6. Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One. 2012;7:e40157. doi: 10.1371/journal.pone.0040157 PMID: 22792233
7. Medarova Z, Pham W, Kim Y, Dai G, Moore A. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer. 2006;118:2796-2802. PMID: 16385568
8. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother. 2002;51:669-673. PMID: 12439613
9. Pichinuk E, Benhar I, Jacobi O, Chalik M, Weiss L, Ziv R, et al. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells. Cancer Res. 2012;72:3324-3336. doi: 10.1158/0008-5472. CAN-12-0067 PMID: 22507854
10. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006;24:252-258. PMID: 16344318
11. Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11:R73. doi: 10.1186/bcr2409 PMID: 19811637
12. Hiroshima Y, Maawy A, Metildi CA, Zhang Y, Uehara F, Miwa S, et al. Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophoreconjugated anti-CEA antibody and a portable imaging system. J Laparoendosc Adv Surg Tech A. 2014;24:241-247. doi: 10.1089/lap. 2013.0418 PMID: 24494971
13. Metildi CA, Kaushal S, Luiken GA, Hoffman RM, Bouvet M. Advantages of fluorescence-guided laparoscopic surgery of pancreatic cancer labeled with fluorescent anti-carcinoembryonic antigen antibodies in an orthotopic mouse model. J Am Coll Surg. 2014;219:132-141. doi: 10.1016/j.jamcollsurg.2014. 02.021 PMID: 24768506
14. Metildi CA, Kaushal S, Pu M, Messer KA, Luiken GA, Moossa AR, et al. Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer. Ann Surg Oncol. 2014;21:1405-1411. doi: 10.1245/s10434-014-3495-y PMID: 24499827
15. Eser S, Messer M, Eser P, Von Werder A, Seidler B, Bajbouj M, et al. In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc Natl Acad Sci U S A. 2011;108:9945-9950. doi: 10.1073/pnas.1100890108 PMID: 21628592
16. Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnouj A, et al. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut. 2013;62:1034-1043. doi: 10. 1136/gutjnl-2012-302577 PMID: 22677720
17. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, et al. Characterization of a new primary human pancreatic tumor line. Cancer Invest. 1986;4:15-23. PMID: 3754176
18. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 1975;15:741-747. PMID: 1140870
19. Bouvet M, Yang M, Nardin S, Wang X, Jiang P, Baranov E, et al. Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clin Exp Metastasis. 2000;18:213-218. PMID: 11315094
20. Hoffman RM, Yang M. Whole-body imaging with fluorescent proteins. Nat Protoc. 2006;1:1429-1438. PMID: 17406431
21. Hoffman RM, Yang M. Color-coded fluorescence imaging of tumor-host interactions. Nat Protoc. 2006;1:928-935. PMID: 17406326
22. Hoffman RM, Yang M. Subcellular imaging in the live mouse. Nat Protoc. 2006;1:775-782. PMID: 17406307
23. Maawy AA, Hiroshima Y, Kaushal S, Luiken GA, Hoffman RM, Bouvet M. Comparison of a chimeric anti-carcinoembryonic antigen antibody conjugated with visible or near-infrared fluorescent dyes for imaging pancreatic cancer in orthotopic nude mouse models. J Biomed Opt. 2013;18:126016. doi: 10. 1117/1. JBO.18.12.126016 PMID: 24356647
24. Uchugonova A, Zhao M, Weinigel M, Zhang Y, Bouvet M, Hoffman RM, et al. Multiphoton tomography visualizes collagen fibers in the tumor microenvironment that maintain cancer-cell anchorage and shape. J Cell Biochem. 2013;114:99-102. doi: 10.1002/jcb.24305 PMID: 22886742
25. Yang M, Jiang P, Hoffman RM. Whole-body subcellular multicolor imaging of tumor-host interaction and drug response in real time. Cancer Res. 2007;67:5195-5200. PMID: 17545599
26. Yamauchi K, Tome Y, Yamamoto N, Hayashi K, Kimura H, Tsuchiya H, et al. Color-coded real-time subcellular fluorescence imaging of the interaction between cancer and host cells in live mice. Anticancer Res. 2012;32:39-43. PMID: 22213286
27. Bouvet M, Wang J, Nardin SR, Nassirpour R, Yang M, Baranov E, et al. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res. 2002;62:1534-1540. PMID: 11888932
28. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992;89:5645-5649. PMID: 1608975
29. Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman RM. A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res. 1993;53:3070-3072. PMID: 8319214
30. Yamauchi K, Yang M, Jiang P, Xu M, Yamamoto N, Tsuchiya H, et al. Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res. 2006;66:4208-4214. PMID: 16618743
31. Kumar P, Lindberg L, Thirkill TL, Ji JW, Martsching L, Douglas GC. The MUC1 extracellular domain subunit is found in nuclear speckles and associates with spliceosomes. PLoS One. 2012;7:e42712. doi: 10.1371/journal.pone.0042712 PMID: 22905162
32. Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M, et al. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol. 2000;11:735-741. PMID: 10942064
33. Prinssen HM, Molthoff CF, Verheijen RH, Broadhead TJ, Kenemans P, Roos JC, et al. Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. Cancer Immunol Immunother. 1998;47:39-46. PMID: 9755877